Advertisement

Pharmacotoxicology of High-Dose Thiotepa

  • Gilles Vassal
  • Olivier Hartmann
Conference paper
Part of the ESO European School of Oncology Monographs book series (ESO MONOGRAPHS)

Abstract

Thiotepa is an alkylating agent that was first synthesised in the 1950s. It can be administered intravenously, intravesically and intrathecally. At conventional doses the main adverse effect is haematopoietic toxicity. For about 10 years now thiotepa has been used at high doses prior to bone marrow transplantation. High-dose thiotepa has been particularly developed in the USA, while high-dose melphalan is preferred in Europe.

Keywords

Bone Marrow Transplantation Conventional Dose Autologous Bone Marrow Transplantation Main Adverse Effect Bone Marrow Rescue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ayash U, Elias A, Wheeler C et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994 12: 37–44PubMedGoogle Scholar
  2. 2.
    Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL: Human pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 1986 70: 859–864PubMedGoogle Scholar
  3. 3.
    Egorin MJ, Snyder SW, Pan S, Daly C: Cellular transport and accumulation of thiotepa. Semin Oncol 1990 17 suppl 3: 7–17Google Scholar
  4. 4.
    Finlay JL, August C, Packer R et al: High-dose multiagent chemotherapy followed by bone marrow rescue for malignant astrocytomas of childhood and adolescence. J Neurol Oncol 1990 9: 239–248CrossRefGoogle Scholar
  5. 5.
    Heidemann RL, Cole DE, Balis F: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989 49: 736–741Google Scholar
  6. 6.
    Henner WD, Shea TC, Furlong EA et al: Pharmacokinetics of continuous infusion of high-dose thiothepa. Cancer Treat Rep 1987 71: 1043–1047PubMedGoogle Scholar
  7. 7.
    Kalifa C, Hartmann O, Demeocq F et al: High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase Il study. Bone Marrow Transplant 1992 9: 227–233PubMedGoogle Scholar
  8. 8.
    Lazarus HM, Reed MC, Spitzer TR, Rabas MS, Blu-mer JL: High-dose in thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987 71: 689–695PubMedGoogle Scholar
  9. 9.
    O’Dwyer PJ, La Creta F, Engstrom PF: Phase I/ pharmacokinetic reevaluation of thiotepa. Cancer Res 1991 51: 3171–3176PubMedGoogle Scholar
  10. 10.
    Przepiorka D, Ippoliti C, Giralt S et al: A phase II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation. Bone Marrow Transplant 1994 14: 449–453PubMedGoogle Scholar
  11. 11.
    Teicher BA, Holden SA, Eder JP, Herman S, Antman K, Frei Ill E: Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 1990 17 suppl 3: 18–32Google Scholar
  12. 12.
    Wolff SN, Herzig RH, Fay JW: High-dose N,N’,N“triethylenethiophosphoramide thiotepa with autologous bone marrow transplantation: phase I studies. Sem Oncol 1990 17 suppl 3: 2–6Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Gilles Vassal
    • 1
  • Olivier Hartmann
    • 1
  1. 1.Paediatric DepartmentInstitut Gustave-RoussyVillejuifFrance

Personalised recommendations